These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 27941528)
1. Efficacy of the Treatments Used in Multiple Sclerosis: From Meta-analysis to Number Needed to Treat. García-Ruiz AJ; Izquierdo-Ayuso G; Navarro-Mascarell G; Montesinos-Gálvez AC; Martos-Crespo F; Jódar-Sánchez F; Correa M; García-Agua Soler N Clin Neuropharmacol; 2017; 40(1):37-42. PubMed ID: 27941528 [TBL] [Abstract][Full Text] [Related]
2. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
3. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F; JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034 [TBL] [Abstract][Full Text] [Related]
4. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. Massacesi L; Tramacere I; Amoroso S; Battaglia MA; Benedetti MD; Filippini G; La Mantia L; Repice A; Solari A; Tedeschi G; Milanese C PLoS One; 2014; 9(11):e113371. PubMed ID: 25402490 [TBL] [Abstract][Full Text] [Related]
5. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S; Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565 [TBL] [Abstract][Full Text] [Related]
6. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297 [TBL] [Abstract][Full Text] [Related]
7. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T; JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031 [TBL] [Abstract][Full Text] [Related]
8. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825 [TBL] [Abstract][Full Text] [Related]
9. Predictors of relapse rate in MS clinical trials. Held U; Heigenhauser L; Shang C; Kappos L; Polman C; Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520 [TBL] [Abstract][Full Text] [Related]
10. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L; Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847 [TBL] [Abstract][Full Text] [Related]
11. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654 [TBL] [Abstract][Full Text] [Related]